Outcomes of interest were overall survival and cause-specific survival of subsequent CRC.

Methods: We identified patients with CRC diagnosed between 1973 and 2008 using the National Cancer Institute’s SEER database.1–3 Outcomes of interest were overall survival and cause-specific survival of subsequent CRC in general, and specifically stage IV disease. Unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models were used to assess the eligibility of enrollment of stage IV CRC patients in clinical trials.

Results: Overall, 550,325 patients with CRC were identified, of whom 31,663 patients had a prior malignancy. Both, history of prior non-leukemic malignancy and prior leukemia were associated with a worse overall survival (HR = 1.165, 95% CI = 1.148–1.183, p < 0.001) and (HR = 1.825, 95% CI = 1.691–1.970, p < 0.001), respectively. However, a history of any prior non-leukemic malignancy showed a favorable colorectal-specific survival (HR = 0.930, 95% CI = 0.909–0.952, P < 0.001). Analysis of stage IV CRC showed that a history of any prior non-leukemic malignancy was not associated with a significant difference in overall survival but having a history of leukemia showed a worse overall survival (HR = 1.535, 95% CI = 1.303–1.809, P < 0.001).

Conclusion: Clinical trials should take these results into consideration when including/excluding stage IV CRC patients with prior malignancies.

References


Impact of prior malignancies on the outcome of colorectal cancer: Revisiting clinical trial eligibility criteria

Anas M. Saad 1,∗, Muneer J. Al-Husseini 1, Hadeer H. Mohamed 1, Mohamad A. Alkhayat 1, Mohamad Bassam Sonbol 2, Omar Abdel-Rahman 3

1 Faculty of Medicine, Ain Shams University, Cairo, Egypt

Aim: To study the impact of prior malignancies on the survival of subsequent CRC.

Methods: We identified patients with CRC diagnosed between 1973 and 2008 using the National Cancer Institute’s SEER database.1–3 Outcomes of interest were overall survival and cause-specific survival of subsequent CRC in general, and specifically stage IV disease. Unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models were used to assess the eligibility of enrollment of stage IV CRC patients in clinical trials.

Results: Overall, 550,325 patients with CRC were identified, of whom 31,663 patients had a prior malignancy. Both, history of prior non-leukemic malignancy and prior leukemia were associated with a worse overall survival (HR = 1.165, 95% CI = 1.148–1.183, p < 0.001) and (HR = 1.825, 95% CI = 1.691–1.970, p < 0.001), respectively. However, a history of any prior non-leukemic malignancy showed a favorable colorectal-specific survival (HR = 0.930, 95% CI = 0.909–0.952, P < 0.001). Analysis of stage IV CRC showed that a history of any prior non-leukemic malignancy was not associated with a significant difference in overall survival but having a history of leukemia showed a worse overall survival (HR = 1.535, 95% CI = 1.303–1.809, P < 0.001).

Conclusion: Clinical trials should take these results into consideration when including/excluding stage IV CRC patients with prior malignancies.

References


Aim: This study aims to investigate the signaling pathway AMP-activated protein kinase (AMPK)-Peroxisome proliferator-activated receptor-gamma coactivator (PGC)1α-SIRT3 in the human corpus cavernosum (HCC) between healthy individuals and those with cardiovascular disease risk factors (CVDRF). 

Introduction: SIRT3 is a mitochondrial NAD+-dependent-protein-deacetylase involved in the regulation of cellular metabolism. As a key factor in AMPK and PGC1α activation in stress, the decrease in SIRT3 expression or activity is associated with diverse pathologies and aging. Actually, SIRT3 expression was found decreased in HCC of aged individuals with CVDRF. CVDRF such as diabetes mellitus (DM), dyslipidemia, hypertension and obesity strongly associate to endothelial dysfunction, which early manifests as erectile dysfunction (ED).

Methods: HCC’s samples from individuals aged 40-60 years, submitted to programmed urological surgeries at Hospital São João-Porto, were divided in three groups (n = 4): (1)-controls without ED or CVDRF; (2)-DM patients; and (3)-patients with three or more CVDRF including DM. Dual immunolabelling of SIRT3 and superoxide dismutase (SOD)2 with alpha-actin was carried out. As well, levels of SIRT1, SIRT3, SOD2, PGC1α, NADPH oxidase (Nox1), phospho-AMPK and AMPK were assessed by Western blotting (WB).

Results: We observed SIRT3 and SOD2 expression in α-actin-labelled fusiform muscle cells in all groups. The semi-quantification by WB demonstrated a significant decrease in SOD2 expression in group 3 relatively to controls, as well as, an increased tendency of Nox1 and PGC1α and a decreasing trend in phospho-AMPK in groups 2 and 3. No differences in SIRT1 and SIRT3 were observed among groups.

Conclusion: This study suggests that CVRF including DM increase oxidative stress in HCC owning to a decrease in SOD2 expression and concomitant increment in Nox1. Further studies with an increased number of HCC samples will be necessary to elucidate the role of the AMPK-PGC1α-SIRT3 signaling pathway in the response to oxidative damage.

Acknowledgements: Adriana R Rodrigues was supported by QREN-POPH, FSE and “Fundação para a Ciência e Tecnologia” (SFRH/BPD/92868/2013).

References


http://dx.doi.org/10.1016/j.pbj.2017.07.090

PS075

Examination of antiproliferative effects of the horseradish extracts

L. Durić1,*, D. Četojević-Simin2, M. Milanović1

1 University of Novi Sad, Faculty of Medicine,
Department of Pharmacy, Novi Sad, Serbia
2 University of Novi Sad, Faculty of Medicine,
Experimental Oncology Department, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
E-mail address: djuriclarisa@gmail.com

Aim: The aim of the study was to investigate in vitro the antiproliferative effects of the horseradish juice and pulp extracts using different solvents for the extraction.

Introduction: Horseradish (Armoracia rusticana, Brassicaceae) is a perennial herbal plant, which is widely used in human nutrition, as well as in a traditional medicine. Horseradish is a rich source of bioactive compounds such as isothiocyanates, that have proved to be significant antitumor agents.

Methods: Samples were prepared by the Kupchak extraction method, and the antiproliferative effects of the horseradish juice and pulp extracts were examined on the human tumor cell line MDA-MB-231 (ER−, human breast adenocarcinoma). Cell growth was determined by measuring the total protein by colorimetric sulforhodamine B assay. The obtained results (expressed as mean ± SD) were analyzed by Tukey HSD test and the differences were considered statistically significant at p < 0.05.

Results: According to the IC50 parameter (the concentration that inhibited the cell growth by 50%), as an important indicator of the antiproliferative effects, the most pronounced antitumor activity was observed for chloroform juice extract (IC50 = 5.52 ± 1.47 μg/ml). In addition, highly potent was chloroform pulp extract (IC50 = 19.44 ± 3.82 μg/ml), as well as the dichloromethane juice (IC50 = 26.50 ± 4.15 μg/ml) and pulp (IC50 = 26, 01 ± 2.45 μg/ml) extracts. On the other hand, significantly lower in vitro antitumor effect was noticed for the butanol pulp extract (IC50 = 114.52 ± 0.28 μg/ml). IC50 values for butanol juice extract, as well as water juice and pulp extracts were higher than 500 μg/ml.

Conclusion: The obtained results suggest that A. rusticana is as a significant source of antitumor agents, especially liposoluble isothiocyanates and as such, it should be recommended for further use in a human nutrition and prevention of cancer.

http://dx.doi.org/10.1016/j.pbj.2017.07.091

PS080

Contribution of the determination of numeric value of adc map in early detection of prostate cancer

Dj Perovic

Faculty of Medicine, University Novi Sad, Serbia
E-mail address: djukaperovic@yahoo.com

Aim: To define the range of ADC values for the absence of malignant disease, as well as to determine the threshold of ADC values for suspected prostate cancer.